The results of this study demonstrated that inhibiting EZH2 suppressed the proliferation of BAP1-mutant MM cell lines, suggesting that EZH2 inhibitors may represent promising candidate therapeutic agents for MM [27]. The gene discussed is BAP1; the disease is Miyoshi myopathy.